BRM and BRG1 Inhibitor Compounds for Selective BAF Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for disorders associated with alterations in the BRG1 and BRM proteins, such as cancer and viral infections, lack effective compounds that can modulate the BAF complex and target BRG1 and BRM activity.
Innovation Solution
Development of compounds that inhibit BRG1 and/or BRM activity, including BRM/BRG1 dual inhibitors and BRM-selective compounds, which can be administered alone or in combination with other pharmaceutically active agents to treat disorders related to the BAF complex.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If BRG1 and BRM activity is inhibited to treat cancer and viral infections, then therapeutic efficacy is improved, but off-target effects and toxicity may increase
Solution Approach 1:
The patent applies local quality by developing selective inhibitors that target specific BRG1 or BRM isoforms with different degrees of selectivity. The compounds are designed to have varying affinities for different BAF complex components, allowing localized inhibition at the desired target while minimizing off-target effects. This is achieved through structural modifications that create preferential binding to specific BRG1/BRM variants.
Solution Approach 2:
The patent employs parameter changes by systematically varying chemical structures to optimize binding affinity and selectivity parameters. Different substituents and molecular configurations are tested to achieve the optimal balance between inhibitory potency and selectivity. This allows tuning of the inhibitor properties to maximize therapeutic effect while minimizing toxicity.
2Reliability
If BAF complex modulation is used to treat disorders, then treatment effectiveness is improved, but compound complexity and development difficulty increase
Solution Approach 1:
The patent applies segmentation by dividing the BAF complex inhibition strategy into separate selective and non-selective inhibitor classes. This allows systematic development and optimization of compounds with specific profiles (BRG1-selective, BRM-selective, or dual inhibitors), making the complex target space more manageable and enabling focused structure-activity relationship studies.
Solution Approach 2:
The patent applies universality by developing a platform of inhibitor compounds that can be adapted for multiple therapeutic applications. The same chemical framework can be used to create inhibitors with different selectivity profiles for treating various cancers and viral infections, reducing the need to develop entirely new compounds for each indication.
Data Source
AI summary
The compounds disclosed herein may be inhibitors of BRG1 (Brahma-related gene-1) and/or BRM (Brahma). The compounds or pharmaceutically acceptable salts thereof are useful for the treatment of disorders associated with an alteration in a BAF complex, e.g., a disorder associated with an alteration in one or both of the BRG1 and BRM proteins. Also disclosed are pharmaceutical compositions containing the compounds or pharmaceutically acceptable salts thereof and methods of their preparation and use.